Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308448540> ?p ?o ?g. }
- W4308448540 abstract "Abstract Introduction Growing data support the safe and efficacious use of ablative radiotherapy in the setting of liver metastases, with some studies suggesting that patients with metastatic breast cancer (MBCa) do better than patients with metastases from other cancers. This study aims to retrospectively review clinical outcomes of patients with MBCa following liver radiotherapy (RT). Materials and Methods Patients with MBCa who received liver hypo fractionated ablative RT between 2004 – 2020 were classified according to metastatic classification and treatment intent (i.e., oligo-metastatic (OM) or oligo-progressive (OP)). Demographics, disease characteristics and treatment characteristics were collated. Primary outcome was local control (LC) of treated metastases. Secondary outcomes included overall survival (OS), progression-free survival (PFS), and time to next line systemic therapy (ST), analyzed by univariate (UVA) and multi-variable analysis (MVA). Results Thirty MBCa patients with 50 liver metastases treated with 5 – 10 fraction ablative intent RT were identified for analysis. Median follow-up was 14.6 months (range 0.9 - 156.2 months). Mean age was 55.6 years (range 32.1 - 79.3 years); 53% were ER+/HER2-ve and 33% HER2+ve. Class of metastatic disease was described as – induced (12 patients, 40%), repeat (15 patients, 50%) and de novo (3 patients, 10%) (1 synchronous, 2 metachronous). Indication of treatment was OP (73%) and OM (27%). Median size of treated liver metastases (LM) was 3.1 cm (range 1cm – 8.8 cm) and the median dose delivered was 40Gy (range 30Gy-60Gy). 1 and 3-year LC rates were 100%. Median OS was 57.7-months with size of treated liver metastases predictive of overall survival (HR 1.35, p=0.023) on UVA. Median time to progression post treatment was 4.8 months (0.8 – 114.7). Patients with induced OMD had a significantly higher rate of progression (HR 4.77, p=0.01) on UVA compared to others, which trended to significance on MVA (HR 3.23, p=0.051). Conclusion Hypo-fractionated ablative liver RT in patients with MBCa provides safe, tolerable treatment with excellent LC. Further studies assessing the impact, ideal sequencing, and indications of RT in each metastatic class in MBCa are required." @default.
- W4308448540 created "2022-11-12" @default.
- W4308448540 creator A5002216968 @default.
- W4308448540 creator A5031828133 @default.
- W4308448540 creator A5038233199 @default.
- W4308448540 creator A5040929178 @default.
- W4308448540 creator A5042445893 @default.
- W4308448540 creator A5045903561 @default.
- W4308448540 creator A5048005267 @default.
- W4308448540 creator A5052975576 @default.
- W4308448540 creator A5070845208 @default.
- W4308448540 creator A5072488977 @default.
- W4308448540 creator A5072824058 @default.
- W4308448540 creator A5081147016 @default.
- W4308448540 creator A5083565293 @default.
- W4308448540 date "2022-11-07" @default.
- W4308448540 modified "2023-10-01" @default.
- W4308448540 title "Clinical Outcomes of Patients with Metastatic Breast Cancer treated with Hypo-Fractionated Liver Radiotherapy" @default.
- W4308448540 cites W1971980519 @default.
- W4308448540 cites W2025000901 @default.
- W4308448540 cites W2071888159 @default.
- W4308448540 cites W2096499183 @default.
- W4308448540 cites W2119384061 @default.
- W4308448540 cites W2239021931 @default.
- W4308448540 cites W2317875558 @default.
- W4308448540 cites W2517804730 @default.
- W4308448540 cites W2591795640 @default.
- W4308448540 cites W2787888453 @default.
- W4308448540 cites W2801291604 @default.
- W4308448540 cites W2893180714 @default.
- W4308448540 cites W2939770857 @default.
- W4308448540 cites W2950824232 @default.
- W4308448540 cites W2974372767 @default.
- W4308448540 cites W3019546741 @default.
- W4308448540 cites W3021410191 @default.
- W4308448540 cites W3022548009 @default.
- W4308448540 cites W3024107212 @default.
- W4308448540 cites W3025990158 @default.
- W4308448540 cites W3091329870 @default.
- W4308448540 cites W3104612125 @default.
- W4308448540 cites W3118437485 @default.
- W4308448540 cites W3129594147 @default.
- W4308448540 cites W3169205666 @default.
- W4308448540 cites W4206748384 @default.
- W4308448540 cites W4283160142 @default.
- W4308448540 doi "https://doi.org/10.21203/rs.3.rs-2234222/v1" @default.
- W4308448540 hasPublicationYear "2022" @default.
- W4308448540 type Work @default.
- W4308448540 citedByCount "0" @default.
- W4308448540 crossrefType "posted-content" @default.
- W4308448540 hasAuthorship W4308448540A5002216968 @default.
- W4308448540 hasAuthorship W4308448540A5031828133 @default.
- W4308448540 hasAuthorship W4308448540A5038233199 @default.
- W4308448540 hasAuthorship W4308448540A5040929178 @default.
- W4308448540 hasAuthorship W4308448540A5042445893 @default.
- W4308448540 hasAuthorship W4308448540A5045903561 @default.
- W4308448540 hasAuthorship W4308448540A5048005267 @default.
- W4308448540 hasAuthorship W4308448540A5052975576 @default.
- W4308448540 hasAuthorship W4308448540A5070845208 @default.
- W4308448540 hasAuthorship W4308448540A5072488977 @default.
- W4308448540 hasAuthorship W4308448540A5072824058 @default.
- W4308448540 hasAuthorship W4308448540A5081147016 @default.
- W4308448540 hasAuthorship W4308448540A5083565293 @default.
- W4308448540 hasBestOaLocation W43084485401 @default.
- W4308448540 hasConcept C121608353 @default.
- W4308448540 hasConcept C126322002 @default.
- W4308448540 hasConcept C143998085 @default.
- W4308448540 hasConcept C144301174 @default.
- W4308448540 hasConcept C19617505 @default.
- W4308448540 hasConcept C2775930923 @default.
- W4308448540 hasConcept C38180746 @default.
- W4308448540 hasConcept C509974204 @default.
- W4308448540 hasConcept C530470458 @default.
- W4308448540 hasConcept C71924100 @default.
- W4308448540 hasConcept C90924648 @default.
- W4308448540 hasConceptScore W4308448540C121608353 @default.
- W4308448540 hasConceptScore W4308448540C126322002 @default.
- W4308448540 hasConceptScore W4308448540C143998085 @default.
- W4308448540 hasConceptScore W4308448540C144301174 @default.
- W4308448540 hasConceptScore W4308448540C19617505 @default.
- W4308448540 hasConceptScore W4308448540C2775930923 @default.
- W4308448540 hasConceptScore W4308448540C38180746 @default.
- W4308448540 hasConceptScore W4308448540C509974204 @default.
- W4308448540 hasConceptScore W4308448540C530470458 @default.
- W4308448540 hasConceptScore W4308448540C71924100 @default.
- W4308448540 hasConceptScore W4308448540C90924648 @default.
- W4308448540 hasLocation W43084485401 @default.
- W4308448540 hasOpenAccess W4308448540 @default.
- W4308448540 hasPrimaryLocation W43084485401 @default.
- W4308448540 hasRelatedWork W144521535 @default.
- W4308448540 hasRelatedWork W1993684647 @default.
- W4308448540 hasRelatedWork W2411890706 @default.
- W4308448540 hasRelatedWork W274490372 @default.
- W4308448540 hasRelatedWork W2784206856 @default.
- W4308448540 hasRelatedWork W2972384824 @default.
- W4308448540 hasRelatedWork W3181412252 @default.
- W4308448540 hasRelatedWork W4200191628 @default.
- W4308448540 hasRelatedWork W4207026578 @default.
- W4308448540 hasRelatedWork W4322772323 @default.
- W4308448540 isParatext "false" @default.